Hans-Peter Guler, MD, Senior Vice President, Clinical Development, joined INC Research in September 2010 as Vice President, Clinical Development. He has over 20 years of experience in the clinical research industry. Prior to joining INC Research, Hans-Peter served as Chief Medical Officer/Vice President Clinical Development at Phenomix for six years. Prior to that, he held positions of increasing responsibility with Ciba-Geigy Corp., Chiron Corp., and Regeneron Pharmaceuticals, Inc.
His work in clinical research included trials at all stages from first in man to large registration trials. Indications studied include diabetes mellitus, obesity, rheumatoid arthritis, hepatitis C, rare diseases, asthma, sepsis, cardiovascular disease, and renal failure. During his tenure at Chiron he led the early efforts (Phase 1 and 2) for Tissue Factor Pathway Inhibitor (TFPI) in sepsis. This included an extensive Phase 1 program in normal volunteers and an early Phase 2 study in septic patients at multiple sites in Europe.
Prior to accepting his first job in industry, he conducted some of the early trials with recombinant insulin-like growth factor I in academia. He is an author of over 30 peer-reviewed articles. Hans-Peter trained in Switzerland and received his MD from the University of Zurich.back to speakers